Clinical Trials Logo

Vomiting clinical trials

View clinical trials related to Vomiting.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT05452174 Terminated - Pregnancy Clinical Trials

Endeavor to Stop Nausea/Vomiting Associated With Pregnancy (E-SNAP)

ESNAP
Start date: June 13, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective of this proposal is to conduct an early Phase 2 clinical trial to determine the acceptability, dosing, tolerability and safety of mirtazapine for severe nausea and vomiting of pregnancy (sNVP) that is not adequately responsive to current standard treatments. This plan mirrors clinical practice since commonly prescribed antiemetic/ antinauseant drugs will be tested for efficacy before treating with mirtazapine.

NCT ID: NCT05065567 Terminated - Clinical trials for Cyclic Vomiting Syndrome

Haloperidol, Droperidol, Ondansetron in Cannabis Hyperemesis

Start date: August 30, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare two commonly used agents for the treatment of cyclic vomiting to see if one agent is inferior to the other in time to improvement in symptoms, need for repeat or rescue medications, treatment failures and complications/side effects.

NCT ID: NCT04721171 Terminated - Clinical trials for Cyclic Vomiting Syndrome

Effectiveness of Electrical Neurostimulation in Cyclic Vomiting Syndrome.

Start date: April 23, 2019
Phase: N/A
Study type: Interventional

We hypothesize that 1) Neurostimulation via a novel auricular percutaneous electrical nerve field stimulation (PENFS) device is a safe, non-invasive opioid-sparing alternative therapy for severe abdominal pain, nausea, and vomiting associated with CVS and will reduce the need for opioids. We also hypothesize that 2) PENFS reduces the length of stay (LOS), and improves patient satisfaction. We propose the following specific aim: Aim 1. Investigate the efficacy of PENFS compared to a sham in patients with CVS seen in the ED or in the clinic or hospitalized with an acute CVS episode. Objectives: 1. Demonstrate reduction in abdominal pain, nausea, and vomiting using validated tools. 2. Obviate or reduce the need for opioids. 3. Reduce the length of hospital stay and improve patient satisfaction. This approach will specifically address the current opioid problem using a novel, non-invasive neurostimulation therapy with proven efficacy for opioid withdrawal. Long-term, it may improve health care outcomes and significantly reduce overall health care costs.

NCT ID: NCT04503668 Terminated - Gynecologic Cancer Clinical Trials

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

Start date: December 28, 2020
Phase: Phase 3
Study type: Interventional

The objective of this study is to investigate the efficacy of olanzapine as compared to neurokinin-1 receptor antagonists (NK1-RAs) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic malignancies receiving single day outpatient chemotherapy (carboplatin and paclitaxel) every 3 weeks.

NCT ID: NCT04478630 Terminated - Nausea Clinical Trials

The Effects of Inhaled Aromatherapy on Chemotherapy Induced Nausea (CINV) and Vomiting

CINV
Start date: August 30, 2021
Phase: N/A
Study type: Interventional

This study is a three group, randomized, double blind, placebo-controlled trial with two repeated measurements. The same measurements will be collected for each participant during two consecutive chemotherapy treatment cycles.Subjects will be provided with written instructions as an educational handout as well as essential oil safety information. Subjects will be able to demonstrate an ability and accurate understanding of the proper use of the diffusers, using a demonstration diffuser, at the time of consent. At the time the subject will provide written informed consent, they will be randomly assigned to one of the three groups with a pocket diffuser containing either ginger essential oil, peppermint essential oil, or vanilla extract )placebo- control). This is based on a pre-determined list of random assignments. Each subject will be instructed to inhale from the pocket diffuser beginning on the day of their chemotherapy (Day 1) and continue using the inhaler for the next three consecutive days (Day 1-Day 4). The subjects will remove the cover of the pocket diffuser, place the pocket diffuser approximately an inch away from their nose and inhale three times with deep breathing (i.e., three sniffs). Subjects will take 3 sniffs of the aromatherapy inhaler three times daily (morning, afternoon, and evening). In addition to the Pre-treatment Assessment, occurring before each of the 2 cycles of chemotherapy, the subjects will be contacted to complete assessments at approximately 24 and 72 hours post-chemotherapy. A member of the study team will call the participant again at their preferred time of day to ask the survey questions. The same procedures will be repeated during the participant's second cycle of chemotherapy, which is likely two or three weeks after the first one.

NCT ID: NCT04188431 Terminated - Pain, Postoperative Clinical Trials

Dexamethasone and Postoperative Bleeding Following Tonsillectomy in Children

Blueberry
Start date: November 1, 2020
Phase: Phase 4
Study type: Interventional

Tonsillectomy is one of the most frequently performed surgical interventions in children. However, it is associated with a high incidence of PostOperative Nausea and Vomiting (PONV), severe pain and haemorrhage. There is strong evidence on the efficacy of Dexamethasone in reducing the incidence of PONV and pain after tonsillectomy, which led to consider this drug as a first line treatment in routine anaesthesia practice in such surgical setting. However, in the last decade, there have been arguments about the potential role of Dexamethasone in increasing the risk of postoperative bleeding in children and studies addressing the haemorrhage risk following administration of Dexamethasone for tonsillectomy are inconclusive.Thus, this study is aimed at providing evidence for the safety profile of Dexamethasone with regard to the risk of post-tonsillectomy bleeding in children when administered as a single intraoperative dose.

NCT ID: NCT03788070 Terminated - Clinical trials for Postoperative Complications

Prevalence of Preoperative Dehydration in Major Elective Urologic Surgery and Its Impact on Postoperative Outcome

DEHYD
Start date: February 12, 2019
Phase:
Study type: Observational

The primary objective of this study is to measure the prevalence of preoperative dehydration in elective major abdominal urologic surgery when we apply our daily standard operation procedures. Secondary objectives are to assess the impact of preoperative dehydration on postoperative outcome. The hypothesis is that preoperative dehydration leads to more postoperative complications.

NCT ID: NCT03785691 Terminated - Clinical trials for Hyperemesis Gravidarum

Validating the Effect og Ondansetron and Mirtazapine in Treating Hyperemesis Gravidarum

VOMIT
Start date: March 1, 2019
Phase: Phase 2
Study type: Interventional

The aim is to investigate the efficacy of mirtazapine and ondansetron as treatment for hyperemesis gravidarum(HG). The setup is a double-blind multicenter trial where patients suffering from HG will be randomized to treatment with either mirtazapine, ondansetron or placebo (1:1:1).

NCT ID: NCT03578952 Terminated - Clinical trials for Aortic Valve Insufficiency

Evaluation of Effectiveness and Safety of Evolut R Valve In Patients With Pure Aortic Regurgitation

Pure AR TAVR
Start date: August 10, 2018
Phase: N/A
Study type: Interventional

This study is to evaluate the efficacy and safety of transcatheter aortic valve replacement (TAVR) in severe 'pure Aortic regurgitation (AR)' using Evolut R valve (Medtronic, Minneapolis, MN).

NCT ID: NCT03276026 Terminated - Clinical trials for Postoperative Nausea and Vomiting

A Study to Compare Neostigmine vs Sugammadex in Length of PACU Stay in Patients Undergoing Sleeve Gastrectomy Surgery

Start date: February 12, 2018
Phase: Phase 4
Study type: Interventional

The investigators will track bariatric patients who received sugammadex versus neostigmine in the post anesthesia care unit until discharge and assess their length of stay and possible nausea / vomiting / hypoxia episodes.